1Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidcnce?[J ]. Mayo Clin Proc, 2002, 77( 10): 1031- 1043. 被引量：1
2Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use[J]. N Engl J Med. 2009, 360( 1 ): 89-110. 被引量：1
3Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort[J]. BMJ, 2010, 341: c4444. 被引量：1
4Cardwell CR, Abner CC, Cantwell MM. et al. Exposttre to oral bisphosphonates and risk o fesophageal cancer[J]. JAMA, 2010, 304(6): 657-663. 被引量：1
5Hcwitt RE. Lissina A, Green AE. et al. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins[J]. Clin Exp Immunol, 2005, 139( 1 ): 101-111. 被引量：1
6Olson K, Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses[J]. J Oncol Pharm Practice, 2007, 13(4): 223-229. 被引量：1
7Reeker RR, Lewiecki EM, Miller PD, et al. Safety of bisphosphonates in the treatment of osteopornsis[J]. Am J Med, 2009, 122, (2 Suppl):S22-S32. 被引量：1
8Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain[J]. Arch Intern Med, 2005, 165(3): 346-347. 被引量：1
9Bock O, Boerst H, Thomasius FE, et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention[J]. J Musculoskelet Neuronal Interact, 2007, 7(2): 144-148. 被引量：1
10Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J]. N Engl J Med. 2007, 356(18): 1809-1822. 被引量：1
3Brandao CM, Machado GP, Acurcio FD.Pharmacoeconomic analysis of strategies to treat posUnenopausal osteoporosis: a systematic review[J]. Rev Bras Reumatol, 2012, 52(6): 924-937. 被引量：1
4Hampson G, Fogelman l.Clinical role of bisphosphonate therapy[J]. Int J Womens Health, 2012, 4: 455-469. 被引量：1
5Napoli N, Armamento-Villareal R.Estrogen hydroxylation in osteoporosis[J]. Adv Clin Chem, 2007, 43:2 l 1-227. 被引量：1
6Seelig MS, Altura BM, Altura BT.Benefits and risks of sex hormone replacement in postrnenopausal women[J]. J Am Coll Nun', 2004, 23(5): 482S-496S. 被引量：1
7Richette P, Roux C. Impact of treatments for osteoporosis on cartilage biomarkers in humans[J]. Osteoporos Int, 2012, 23, 8: 877-880. 被引量：1
8Levis S, Theodore G. Summary of AHRQ's comparative effectiveness review of treatment to prevent fiactures in men and women with low bone density or osteoporosis: update of the 2007 report[J]. J Manag Care Pharm, 2012, 18(4 Suppl B): SI-S15. 被引量：1
9Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with posUrlenopausal osteoporosis[J]. CalcifTissue Int, 2011, 89(2): 91-104. 被引量：1
10Lin T, Wang C, Cai XZ, et al.Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis[J]. Int J Clin Pmct, 2012, 66(4): 399-408. 被引量：1
